Warning Letter — Indiangoods.shop
The FDA issued a warning letter to Indiangoods.shop for distributing unapproved new drugs and misbranded drugs via their website. The agency's Center for Drug Evaluation and Research (CDER) identified violations related to the sale of products without approved applications.
This affects the operators of Indiangoods.shop, online drug retailers, and regulatory compliance officers overseeing e-commerce pharmaceutical distribution.
This enforcement action indicates ongoing FDA scrutiny of online platforms bypasssing the drug approval process. Marketing products as drugs without FDA approval or proper labeling constitutes a significant regulatory violation, potentially leading to seizure or injunction if not remediated. The source suggests the agency is actively monitoring digital marketplaces for non-compliant therapeutic claims and the unauthorized sale of prescription-grade items.
Retailers and e-commerce platforms should conduct immediate audits of their product listings to ensure no prescription-only drugs are being marketed directly to consumers. Regulatory teams must verify that all drug claims are supported by approved applications and that labeling complies with federal requirements to avoid misbranding charges.
FDA Warning Letter issued to: Indiangoods.shop. 06/17/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/indiangoodsshop-729068-06172026
Open in openFDA / FDA.gov